Lung Cancer Clinical Trials in Houston

Showing 321-331 of 331 trials

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

NCT00048087

Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy. A course of therapy is 4 weeks. Patients will not receive docetaxel during week 4. A maximum of 8 full cycles of docetaxel plus Iressa are planned. Patients may continue on daily Iressa until progressive disease and/or unacceptable toxicity.

Non-small Cell Lung Cancer

M.D. Anderson Cancer CenterStarted Aug 2002

Houston, Texas, United States

COMPLETEDPHASE3< 1 mile

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

NCT00050960

This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

Non-small Cell Lung Cancer

Eisai Inc.612 participantsStarted May 2002

Montgomery, Alabama, United States • Tucson, Arizona, United States • Concord, California, United States +151 more locations

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Lung Cancer Trials in Other Cities

TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Study of XL281 in Adults With Solid Tumors

Other Conditions in Houston